Long-term outcomes of transoral incisionless fundoplication for gastro-esophageal reflux disease: systematic-review and meta-analysis (original) (raw)
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(02): E239-E246
DOI: 10.1055/a-1322-2209
Sabrina Testoni‡
1Division of Pancreatico-Biliary Endoscopy & Endosonography, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Milan, Italy
Cesare Hassan‡
2Ospedale Nuovo Regina Margherita, Digestive Endoscopy Unit, Rome, Italy
,
Giorgia Mazzoleni
3Ospedale di Treviglio – Caravaggio, ASST Bergamo Ovest, Digestive Endoscopy Unit, Bergamo, Italy
,
Giulio Antonelli
2Ospedale Nuovo Regina Margherita, Digestive Endoscopy Unit, Rome, Italy
,
Lorella Fanti
4Division of Gastroenterology & Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
,
Sandro Passaretti
4Division of Gastroenterology & Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
,
Loredana Correale
5Im3D Clinic Piemonte S.c.a.r.l., Medical Imaging Lab, Torino, Italy
,
Giulia Martina Cavestro
4Division of Gastroenterology & Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
,
Pier Alberto Testoni
4Division of Gastroenterology & Gastrointestinal Endoscopy, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy
Abstract
Background and study aims Few reports exist about long-term outcomes of transoral incisionless fundoplication (TIF) for treating refractory gastro-esophageal reflux disease (GERD).
Methods A literature search of four major scientific databases was performed up to May 2020 for studies reporting on more than 3-year outcomes of TIF. Data on atient satisfaction, proton pump inhibitor (PPI) daily consumption, PPI use reduction, GERD health-related quality-of-life (GERD-HRQL) score, and normalization of heartburn and regurgitation scores were pooled and summarized with forest plots. Publication bias and heterogeneity were explored.
Results Overall, eight studies (418 patients, 232 men; 55.5 %) with a mean follow-up of 5.3 years (range: 3–10 years) were included. The pooled proportion of patient-reported satisfaction before and after TIF was 12.3 % (95 % CI:12.3–35.1 %, I2 = 87.4 %) and 70.6 % (95 % CI:51.2–84.6, I2 = 80 %), respectively, corresponding to an odds ratio of 21.4 (95 % CI:3.27–140.5). Pooled rates of patients completely off PPIs and on occasional PPIs were 53.8 % (95 %CI: 42.0 %-65.1 %) and 75.8 % (95 %CI: 67.6–82.6), respectively. The pooled estimated mean GERD-HRQL scores off PPI before and after TIF werey 26.1 (95 %CI: 21.5–30.7; range: 20.0–35.5) and 5.9, respectively (95 %CI:0.35.1–11.4; range: 5.3–9.8; P < 0.001). The overall pooled rates of heartburn and regurgitation scores normalization were 73.0 % (95 %CI: 0.62–0.82) and 86 %, respectively (95 %CI: 75.0–91.0 %).
Conclusion Our study shows that TIF appears to offer a long-term safe therapeutic option for selected patients with GERD who refuse life-long medical therapy or surgery, are intolerant to PPIs, or are at increased surgical risk.
Publication History
Received: 15 July 2020
Accepted: 20 October 2020
Article published online:
03 February 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1 Huang X, Chen S, Zhao H. et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc 2017; 31: 1032-1044
2 McCarty TR, Itidiare M, Njei B. et al. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy 2018; 50: 708-725
3 Richter JE, Kumar A, Lipka S. et al. Efficacy of laparoscopic nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. Gastroenterology 2018; 154: 1298-1308
4 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94
5 Moga C, Guo B, Schopflocher D. et al. Development of a quality appraisal tool for case series studies using a modified Delphi technique. Inst Health Econ; 2012 Available at: https://www.ihe.ca/advanced-search/development-of-a-quality-appraisal-tool-for-case-series-studies-using-a-modified-delphi-technique
6 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12
7 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
8 Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods 2010; 1: 112-125
9 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analyses detected by a simple graphical test. BMJ 1997; 315: 629-634
10 Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Statist Software 2010; 36: 1-48
11 Muls V, Eckardt AJ, Marchese M. et al. Three-year results of a multicenter prospective study of transoral incisionless fundoplication. Surgical Innovation 2013; 20: 321-330
12 Witteman PBL, Strijkers R, de Vries E. et al. Transoral incisionless fundoplication for treatment of gastroesophageal reflux diseases in clinical practice. Surg Endosc 2012; 26: 3307-3315
13 Roy-Shapira A, Bapaye A, Date S. et al. Trans-oral anterior fundoplication: 5-year follow-up of pilot study. Surg Endosc 2015; 29: 3717-3721
14 Kim HJ, Kwon CI, Kessler WR. et al. Long-term follow-up results of endoscopic treatment of gastroesophageal reflux disease with the MUSE™ endoscopic stapling device. Surg Endosc 2016; 30: 3402-3408
15 Trad KS, Barnes WE, Prevou ER. et al. The TEMPO trial at 5 years: transoral fundoplication (TIF 2.0) is safe, durable, and cost-effective. Surg Innov 2018; 25: 149-157
16 Stefanidis G, Viazis N, Kotsikoros N. et al. Long-term benefit of transoral incisionless fundoplication using the Esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. Dis Esophagus 2017; 30: 1-8
17 Testoni PA, Testoni S, Distefano G. et al. Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years. Endosc Int Open 2019; 7: E647-E654
18 Chimukangara M, Jalilvand AD, Melvin WS. et al. Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study. Surg Endosc 2019; 33: 1304-1309
19 Loedrup A, Pottegard A, Hallas J. et al. Use of proton pump inhibitors after antireflux surgery. A nationwide register-based follow-up study. Gut 2014; 63: 1544-1549
20 Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev 2015; 11: CD003243
21 Lundell L, Bell M, Ruth M. Systematic review: laparoscopic fundoplication for gastro-esophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol 2014; 20: 804-813
22 Kelly JJ, Watson DI, Chin KF. et al. Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg 2007; 205: 570-575
23 Gunter RL, Shada AL, Funk LM. et al. Long-term quality of life outcomes following Nissen versus Toupet fundoplication in patients with gastroesophageal reflux disease. J Laparoendosc Adv Surg Tech A 2017; 27: 931-936